The current landscape of gastric cancer and gastroesophageal junction cancer diagnosis and treatment in China: a comprehensive nationwide cohort analysis
Journal of Hematology & Oncology, 2025
Globally, gastric cancer (GC) is associated with significant risk of comorbidity and death. Since the condition is particularly prevalent in China, there is a critical need to understand the effectiveness of treatments for patients with GC in the country. Yet, there is limited real-world evidence (RWE) about treatment strategies or their effect on outcomes for patients with GC in China.
To provide that evidence, an Analysis Group team led by Vice President Jia Zhong collaborated with researchers from Peking University Cancer Hospital (PUCH, 北京大学肿瘤医院) and the Mayo Clinic to analyze electronic health records (EHRs) from more than 220,000 patients with gastric and gastroesophageal junction cancer in China. The study was part of a broader partnership between Analysis Group and PUCH aimed at improving patient care through RWE studies across multiple disease areas. Through this partnership, AG collaborates with PUCH to leverage its extensive network and clinical resources, generating regulatory-grade evidence that is tailored to the Chinese market.
Utilizing data extracted from the National Cancer Information Database – which is integrated with the National Central Cancer Registry of China – the researchers observed trends in outcomes and treatment effectiveness for patients across 53 hospitals and 27 provinces. In an article on their research, the authors investigated the clinicopathological characteristics, first- and second-line treatment regimens, disease prognoses, and survival outcomes among the patients studied. Among other findings, the authors report evolving treatment trends in China, including broader use of triplet chemotherapy and immunotherapy. This reflects increasing alignment with global best practices and a move toward more personalized approaches to gastric cancer care in China. The researchers conclude that “[t]he present findings provide insights into the existing framework of GC management in China and inform and influence forthcoming treatment strategies to improve the clinical outcomes of patients with GC.”
“This study deepens our understanding of treatment efficacy and prognosis among patients with gastric and gastroesophageal junction cancer,” remarked Analysis Group Managing Principal Eric Wu. “Research on large-scale real-world data like this can help improve patient management globally.”
The article, “The current landscape of gastric cancer and gastroesophageal junction cancer diagnosis and treatment in China: a comprehensive nationwide cohort analysis,” was published in the Journal of Hematology & Oncology.
Authors
Chen Y, Jia K, Xie Y, Yuan J, Liu D, Jiang L, Peng H, Zhong J, Li J, Zhang X, Shen L